Pharmacokinetics of Hu-Pi-Cheng-Qi Decoction Administered via Enema to Rats with Acute Pancreatitis

0
0
0

Pharmacokinetics of Hu-Pi-Cheng-Qi Decoction Administered via Enema to Rats with Acute Pancreatitis

Acute pancreatitis (AP) is a prevalent digestive disorder characterized by inflammation of the pancreas, often requiring interventions that restore gastrointestinal function. Traditional Chinese medicine (TCM) formulations, such as Da-Cheng-Qi decoction (DCQD), have shown clinical efficacy in managing AP by purging pathogenic heat and toxins while regulating intestinal motility. Building on these principles, Hu-Pi-Cheng-Qi decoction (HPCQD) was developed as an enhanced formulation of DCQD by incorporating Huzhang (Polygonum cuspidatum) and Gualoupi (Trichosanthes peel) to strengthen its effects on purging the Fu-Organs and ventilating lung function. This study investigates the pharmacokinetics, tissue distribution, and absorption characteristics of HPCQD administered via enema to AP-induced rats, providing critical insights into its therapeutic mechanisms.

Formulation and Preparation of HPCQD

HPCQD comprises six herbal components: Dahuang (Rheum palmatum, 12 g), Gualoupi (15 g), Houpu (Magnolia officinalis, 15 g), Huzhang (15 g), Mangxiao (Sodium sulfate, 10 g), and Zhishi (Citrus aurantium, 12 g). The herbs were processed into spray-dried granules, dissolved in ultrapure water (50–60°C), and stirred for 30 minutes to achieve a final concentration of 1.2 g/mL. This standardized preparation ensured consistency in bioactive compound delivery during enema administration.

Experimental Design and Animal Model

Twelve male Sprague-Dawley rats (200–250 g) were acclimatized for two weeks and randomly divided into normal (NG) and experimental (EG) groups (n=6 each). AP was induced in the EG group using a validated model involving intraperitoneal injections of L-arginine (250 mg/100 g body weight) to mimic pancreatic inflammation. At 12 hours post-induction, both groups received 1.2 g/mL HPCQD via rectal enema. Blood samples (0.5 mL) were collected from caudal veins at 13 intervals (5, 10, 20, 30 minutes; 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours). Subcutaneous saline (5 mL) was administered post-sampling to maintain hydration. After 24 hours, lung, pancreatic, and colon tissues were harvested for analysis.

Analytical Methods and Pharmacokinetic Parameters

High-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) quantified five bioactive components in serum and tissues: emodin (anthraquinone), hesperidin (flavonoid), magnolol (phenolic), polydatin (stilbene), and vanillic acid (phenolic acid). Pharmacokinetic parameters, including time to peak concentration (Tmax) and tissue distribution, were calculated using GraphPad Prism 6.01. Statistical significance (P<0.05) was determined via Dunnett tests and one-way repeated-measure ANOVA.

Serum Pharmacokinetics

  • Tmax: In AP rats, Tmax for all components occurred at 30 minutes (0.5 h), indicating delayed absorption compared to NG rats, where Tmax for emodin, magnolol, polydatin, and vanillic acid occurred earlier.
  • Concentration-Time Curves: Hesperidin exhibited the highest serum concentration in EG, followed by vanillic acid and magnolol. Emodin and polydatin showed lower systemic exposure, suggesting partial degradation or rapid tissue uptake.

Tissue Distribution

Tissue analysis revealed organ-specific accumulation of components:

  • Lungs:
    • Polydatin levels were significantly lower in EG (P<0.05 vs. NG), potentially due to increased utilization in resolving inflammation.
    • Magnolol concentrations increased by 40% in EG (P<0.05), attributed to its lipophilic properties facilitating passive diffusion into inflamed tissues.
  • Colon:
    • Magnolol accumulation in EG was 2.1-fold higher than NG (P<0.05), aligning with HPCQD’s therapeutic focus on gastrointestinal recovery.
    • Emodin and vanillic acid showed moderate retention, likely due to their roles in mitigating oxidative stress.
  • Pancreas:
    • Hesperidin and vanillic acid predominated, with concentrations 1.8-fold higher in EG (P<0.05), indicating targeted anti-inflammatory effects.

Mechanistic Insights and Therapeutic Implications

The differential distribution of HPCQD components underscores their unique pharmacodynamic roles:

  1. Magnolol: Its high lipophilicity enables rapid absorption into lipid-rich tissues, such as inflamed lungs and colon. Magnolol suppresses NF-κB signaling, reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6) and oxidative stress markers (e.g., malondialdehyde).
  2. Polydatin: Reduced levels in AP lungs suggest enhanced metabolism or binding to inflammatory mediators. Polydatin’s antioxidative properties likely mitigate reactive oxygen species (ROS) overproduction, though its rapid clearance in AP necessitates further study.
  3. Emodin and Hesperidin: These components modulate intestinal immune responses. Emodin inhibits pancreatic enzyme activation, while hesperidin enhances mucosal barrier repair via TGF-β pathways.
  4. Vanillic Acid: As a hydroxyl radical scavenger, it reduces lipid peroxidation in pancreatic acinar cells, preserving membrane integrity.

Conclusion

This study delineates the pharmacokinetic and tissue distribution profiles of HPCQD in AP, highlighting magnolol as a key therapeutic agent targeting pulmonary and colonic inflammation. The delayed Tmax in AP rats reflects altered absorption kinetics under inflammatory states, while tissue-specific accumulation aligns with TCM principles of organ targeting. These findings validate the clinical use of HPCQD enemas in AP management and provide a foundation for isolating bioactive components for drug development. Future research should explore dose optimization, drug interactions, and long-term safety to enhance translational applicability.

doi.org/10.1097/CM9.0000000000000853

Was this helpful?

0 / 0